BioAge Labs, Inc. (BIOA)
5.35
-0.07
(-1.29%)
USD |
NASDAQ |
Oct 15, 16:00
5.36
+0.01
(+0.19%)
After-Hours: 20:00
BioAge Labs Cash from Operations (TTM) : -87.60M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -87.60M |
| March 31, 2026 | -88.31M |
| December 31, 2025 | -81.63M |
| September 30, 2025 | -58.51M |
| June 30, 2025 | -57.40M |
| March 31, 2025 | -53.21M |
| Date | Value |
|---|---|
| December 31, 2024 | -51.52M |
| September 30, 2024 | -54.89M |
| June 30, 2024 | -47.72M |
| March 31, 2024 | -43.03M |
| December 31, 2023 | -37.36M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Neumora Therapeutics, Inc. | -180.96M |
| Alumis, Inc. | -351.40M |
| ANI Pharmaceuticals, Inc. | 189.47M |
| Corcept Therapeutics, Inc. | 109.70M |
| Veru, Inc. | -26.04M |